Announcements Trials

Browse Landscape

Phase

Status

Completed 5 Terminated 2 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8 Genitourinary 4 Thoracic 3 Tumor-Agnostic 2 Sarcoma 2 Other solid neoplasm 2 Lymphoid 2 Head & Neck 2 Dermatologic 2 Breast 2 Other hematologic neoplasm 1 Gynecologic 1 CNS 1

Conditions

Interventions

Temozolomide 66 Radiotherapy 52 Carboplatin 25 Bevacizumab 21 Cisplatin 19 Radiosurgery 18 Vincristine 17 Etoposide 17 Cyclophosphamide 17 Surgical Procedures, Operative 13 Magnetic Resonance Spectroscopy 13 Chemotherapy, Adjuvant 11 Melphalan 10 Lomustine 10 Drug Therapy 10 Filgrastim 9 Erlotinib Hydrochloride 9 apatinib 8 Pemetrexed 8 3-Iodobenzylguanidine 8 anlotinib 7 Radiation 7 Peripheral Blood Stem Cell Transplantation 7 Methotrexate 7 Thiotepa 6 Isotretinoin 6 Irinotecan 6 Ifosfamide 6 Doxorubicin 6 Carmustine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × avelumab × CNS × Clear all

NCT03750071 2022-10-20

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Vaximm GmbH

Phase 1/2 Unknown

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡